Molecular phenotypes of colorectal cancer and potential clinical applications
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease, arising from many possible etiological pathways. This heterogeneity can have important implications for CRC prognosis and clinical management. Epidemiological studies of CRC risk and prognosis-as well as clinical trials for the treatment of CRC-must therefore be sensitive to the molecular phenotype of colorectal tumors in patients under study. In this review, we describe four tumor markers that have been widely studied as reflections of CRC heterogeneity: (i) microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency, (ii) the CpG island methylator phenotype (CIMP), and somatic mutations in (iii) BRAF and (iv) KRAS. These tumor markers have been used to better characterize CRC epidemiology and, increasingly, may be used to guide clinical decision-making. Going beyond these traditional tumor markers, we also briefly review some more novel markers likely to be of clinical significance. Lastly, recognizing that none of these individual tumor markers are isolated attributes but, rather, a reflection of broader tumor phenotypes, we review some of the hypothesized etiological pathways of CRC development and their associated clinical differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777 · cited 1×
“termed ‘CpG islands’, which are found in the promoter regions of roughly half of all genes [27].”
BackgroundWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Specifically, responses were observed in patients whose tumors did not exhibit KRAS exon 2 mutations, while no response—or even harm—was seen in patients with KRAS-mutant tumors [66, 67].”
BackgroundPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“studies have now shown that KRAS testing restricted to exon 2 misses 15–17% of cases resistant to anti-EGFR therapy [68, 69].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 1×
“In particular, MSI has been shown to predict lack of benefit from adjuvant 5-FU in Stage II–III colon cancer (and possible harm in Stage II patients) [20]; however, the value of an MSI as a predictive marker with modern combination chemotherapy regimens—such as FOLFOX and FOLFIRI (5-FU with iri-”
BackgroundLong-term colorectal-cancer incidence and mortality after lower endoscopy
Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z. R., Inamura, K., Kim, S. A., Kuchiba, A., Yamauchi, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301969 · Cited by 1,483
Cited by
Picard, E., Verschoor, C. P., Ma, G. W., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 522
O’Neil, B. H., Wallmark, J. M., Lorente, D., Elez, E., Raimbourg, J., Gomez-Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Abdul Razak, A. R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189848 · Cited by 296
Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location
Mima, K., Cao, Y., Chan, A. T., Qian, Z. R., Nowak, J. A., Masugi, Y., Shi, Y., Song, M., da Silva, A., Gu, M., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.53 · Cited by 284
Dysbiosis of gut microbiota in promoting the development of colorectal cancer
Zou, S., Fang, L., & Lee, M.-H. (2018) · Gastroenterology Report · doi:10.1093/gastro/gox031 · Cited by 280
Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer
Purcell, R. V., Visnovska, M., Biggs, P. J., Schmeier, S., & Frizelle, F. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11237-6 · Cited by 227
Metadata
- Authors
- Kocarnik, J. M., Shiovitz, S., & Phipps, A. I.
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-03
- Volume
- 3
- Issue
- 4
- Pages
- gov046
- ISSN
- 2052-0034 (ISSN-L)
- OpenAlex
- W2244314249
- Cited by
- 132
- References
- 18
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular phenotypes of colorectal cancer and potential clinical applications. https://app.cochat.ai/papers/10.1093/gastro/gov046
- The paper
- Kocarnik, J. M., Shiovitz, S., & Phipps, A. I. (2015). Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterology Report. https://doi.org/10.1093/gastro/gov046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.